Acadia Healthcare Co. (NASDAQ:ACHC) fell 2.3% on Wednesday . The company traded as low as $48.90 and last traded at $49.03, with a volume of 555,114 shares trading hands. The stock had previously closed at $50.20.

Several equities research analysts have weighed in on the company. Robert W. Baird reissued an “outperform” rating and issued a $69.00 price target on shares of Acadia Healthcare in a report on Tuesday, June 14th. Zacks Investment Research cut Acadia Healthcare from a “hold” rating to a “sell” rating in a research note on Monday, July 11th. RBC Capital Markets restated an “outperform” rating and issued a $78.00 price objective (down from $86.00) on shares of Acadia Healthcare in a research note on Monday, August 1st. Leerink Swann restated an “outperform” rating and issued a $90.00 price objective on shares of Acadia Healthcare in a research note on Friday, July 15th. Finally, Royal Bank Of Canada reduced their price objective on Acadia Healthcare from $86.00 to $78.00 and set an “outperform” rating for the company in a research note on Monday, August 1st. One equities research analyst has rated the stock with a sell rating and twelve have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $78.46.

The firm has a market capitalization of $4.30 billion, a price-to-earnings ratio of 26.29 and a beta of 0.84. The company’s 50 day moving average price is $51.60 and its 200-day moving average price is $55.47.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/acadia-healthcare-co-achc-shares-down-2-3.html

Acadia Healthcare (NASDAQ:ACHC) last posted its quarterly earnings results on Friday, July 29th. The company reported $0.73 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.73. The company had revenue of $756.50 million for the quarter, compared to analysts’ expectations of $752.57 million. Acadia Healthcare had a return on equity of 9.35% and a net margin of 6.44%. The firm’s revenue was up 66.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.57 earnings per share. On average, equities analysts anticipate that Acadia Healthcare Co. will post $2.64 EPS for the current fiscal year.

In other Acadia Healthcare news, major shareholder Waud Capital Partners Iii, L.L sold 457,443 shares of the company’s stock in a transaction on Friday, September 16th. The stock was sold at an average price of $48.39, for a total value of $22,135,666.77. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO David M. Duckworth sold 16,670 shares of the company’s stock in a transaction on Monday, August 15th. The shares were sold at an average price of $54.33, for a total value of $905,681.10. Following the completion of the transaction, the chief financial officer now directly owns 11,688 shares in the company, valued at approximately $635,009.04. The disclosure for this sale can be found here. 17.20% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of ACHC. Wellington Management Group LLP boosted its position in Acadia Healthcare by 97.2% in the first quarter. Wellington Management Group LLP now owns 6,983,799 shares of the company’s stock valued at $384,877,000 after buying an additional 3,441,579 shares in the last quarter. Pennant Capital Management LLC bought a new position in Acadia Healthcare during the first quarter valued at about $83,685,000. American Century Companies Inc. bought a new position in Acadia Healthcare during the second quarter valued at about $56,657,000. JPMorgan Chase & Co. boosted its position in Acadia Healthcare by 17.7% in the first quarter. JPMorgan Chase & Co. now owns 4,748,547 shares of the company’s stock valued at $261,693,000 after buying an additional 715,472 shares in the last quarter. Finally, TCW Group Inc. boosted its position in Acadia Healthcare by 32.2% in the second quarter. TCW Group Inc. now owns 1,828,660 shares of the company’s stock valued at $101,308,000 after buying an additional 445,200 shares in the last quarter.

About Acadia Healthcare

Acadia Healthcare Company, Inc is a provider of behavioral healthcare services. The Company operates in two segments: U.S. Facilities and U.K. Facilities. The Company develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities and facilities providing outpatient behavioral healthcare services to serve the behavioral health and recovery needs of communities throughout the United States, the United Kingdom and Puerto Rico.

5 Day Chart for NASDAQ:ACHC

Receive News & Ratings for Acadia Healthcare Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acadia Healthcare Co. and related companies with MarketBeat.com's FREE daily email newsletter.